Morgan Stanley Vaxcyte, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Morgan Stanley holds 694,869 shares of PCVX stock, worth $60.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

694,869

Previous 409,692 69.61%

Holding current value

$60.1 Million

Previous $30.9 Million 156.45%

% of portfolio

0.01%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $20.1 Million - $33.4 Million	285,177 Added 69.61%	694,869 $79.3 Million
Q2 2024 Oct 17, 2024	SELL	$60.06 - $78.77 $4.85 Million - $6.36 Million	-80,762 Reduced 16.47%	409,692 $30.9 Million
Q2 2024 Aug 14, 2024	SELL	$60.06 - $78.77 $4.85 Million - $6.36 Million	-80,762 Reduced 16.47%	409,692 $30.9 Million
Q1 2024 Oct 17, 2024	BUY	$59.79 - $81.05 $4.83 Million - $6.55 Million	80,762 Added 19.71%	490,454 $33.5 Million
Q1 2024 Aug 16, 2024	SELL	$59.79 - $81.05 $2.8 Million - $3.8 Million	-46,911 Reduced 8.73%	490,454 $33.5 Million
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $2.8 Million - $3.8 Million	-46,911 Reduced 8.73%	490,454 $33.5 Million
Q4 2023 Aug 16, 2024	BUY	$45.35 - $63.41 $5.79 Million - $8.1 Million	127,673 Added 31.16%	537,365 $33.7 Million
Q4 2023 Feb 13, 2024	BUY	$45.35 - $63.41 $5.8 Million - $8.1 Million	127,815 Added 31.21%	537,365 $33.7 Million
Q3 2023 Nov 15, 2023	SELL	$46.0 - $53.1 $714,840 - $825,174	-15,540 Reduced 3.66%	409,550 $20.9 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $8.82 Million - $13.8 Million	254,467 Added 149.14%	425,090 $21.2 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $90,965 - $118,377	2,508 Added 1.49%	170,623 $6.39 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $2.58 Million - $6.02 Million	125,582 Added 295.26%	168,115 $8.06 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $2.06 Million - $2.71 Million	-95,138 Reduced 69.11%	42,533 $1.02 Million
Q2 2022 Oct 27, 2022	BUY	$17.68 - $26.58 $861,723 - $1.3 Million	48,740 Added 54.81%	137,671 $3 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $861,723 - $1.3 Million	48,740 Added 54.81%	137,671 $3 Million
Q1 2022 Oct 27, 2022	SELL	$17.46 - $26.36 $851,000 - $1.28 Million	-48,740 Reduced 35.4%	88,931 $2.15 Million
Q1 2022 May 13, 2022	BUY	$17.46 - $26.36 $542,796 - $819,479	31,088 Added 53.75%	88,931 $2.15 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $381,898 - $522,837	19,767 Added 51.91%	57,843 $1.38 Million
Q3 2021 Nov 15, 2021	BUY	$20.26 - $26.97 $771,419 - $1.03 Million	38,076 New	38,076 $966,000

Others Institutions Holding PCVX

# of Institutions

353

Shares Held

122M

Call Options Held

775K

Put Options Held

433K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.13B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account